Navigation Links
Innolife Pharma Inc. acquires rights to breakthrough in non-narcotic chronic pain treatment
Date:5/20/2008

Relief soon to be widely available for chronic pain sufferers.

MARKHAM, ON, May 20 /PRNewswire-FirstCall/ - Innolife Pharma, Inc. (Other OTC:INNP.PK - News) is pleased to announce that it has acquired North American licensing rights to the Natural Pain Relief Center non-narcotic proprietary breakthrough in the treatment of chronic pain.

Today, one in five Americans suffer with chronic pain (~ 60 million adults) spending approximately $120 Billion a year and the aging baby boomers have reported in surveys more aches and pains than any previous generation.

New Medical Finding with Brain Scans and Functional MRI's

Modern Brain Imaging has revealed that most chronic pain is the result of the brain's inability to turn off pain messages from the body. In chronic pain the brain simply is not producing and releasing enough natural pain killers (such as endorphins) to stop the person's suffering. These new medical findings show that chronic pain sufferers from headaches, migraines, fibromyalgia, back pain, sciatica, arthritis or a combination of all of them, are caused by a low level of Natural Pain Killer's (such as Endorphins and others) in the brain, as compared to people without chronic pain.

Over three years of in-clinic testing showed that this breakthrough all-natural program relieved significant chronic pain in 8 out of 10 people and with sustainable results. This non-narcotic, combination treatment has been receiving accolades from chronic pain sufferers with major improvement in mood and energy and dramatic decreases in pain levels, allowing a return to normal life function.

Innolife Pharma Inc. has an aggressive growth plan in place with a projected target of 95 licensed clinics in 3 years with projected top line annual revenue in excess of $30 million and a projected bottom line profit of over $12 million annually (40+%).

With the aging demographic, chronic pain is becoming a larger and larger internation
'/>"/>

SOURCE Innolife Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Sickle cell disease, a condition characterized ... one of the most common genetic blood disorders ... more than 70,000 Americans.(1) Research presented today at ... of Hematology highlights intriguing studies on the acute ... with this blood disorder, evaluations of both new ...
(Date:12/6/2009)... Dec. 6, 2009 A new study provides welcome ... as venous thromboembolism (VTE). , The condition is ... year, and occurs when an abnormal clot forms in ... pain and swelling. In some cases, the clot may ... the heart to the lungs, causing a potentially fatal ...
(Date:12/6/2009)... and members of the community, in cooperation with the Greater VA ... holiday party. This year,s attendance is expected to soar to more ... , ... (PRWEB) December 6, 2009 -- Volunteer organizations ... Healthcare System in West Los Angeles, will once again create a ...
(Date:12/5/2009)... shown in a phase 1/2 clinical trial that ... of patients newly diagnosed with multiple myeloma, a cancer ... from Dana-Farber Cancer Institute. , Partial responses or better ... with the drug combination in the multi-center study, with ... in the phase 2 population, reports Paul G. Richardson, ...
(Date:12/5/2009)... What: Cuts for a Cause ,, ... cancer and other terminal illnesses affecting children. All proceeds from ... Children,s Research Hospital. Guests will enjoy complimentary beverages and hors ... restaurant in Falls Church for all guests. Hoa Lai, a ...
Breaking Medicine News(10 mins):Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2
... eco-bedroom tips, pillow giveaway and Danny Seo appearance on HSN. ... ... celebration of Earth Day, Simmons Bedding Company is encouraging ... that include the company,s Natural Care® mattress and pillow collection, which ...
... MMR Information Systems, Inc., which through its ... Web-based consumer-controlled Personal Health Records ("PHRs") ( ... storage solutions ( www.myesafedepositbox.com ), announced ... FVRL to MMRF effective upon market opening on ...
... needs in skilled nursing facilitiesCOLUMBUS, Ohio, April 21 ... Coalition, the umbrella group representing Ohio,s skilled nursing ... state budget bill unveiled by House Democrats. The ... Ohio,s frail elderly and disabled citizens that would ...
... 21 New research with actionable insights on critical ... now available in the Best Practice Database, an online ... Practices, LLC.To review key topics in these studies, go ... the two new studies at this address: ...
... Continuing Series of Podcasts from Perot Systems on the Impact of Technology on HealthcarePLANO, ... Harry Greenspun, executive vice president and chief, ... Guests: Tom Leary, senior director of Federal Affairs for Healthcare, ... Society (HIMSS), ...
... of losses in past 3 years; Medical care spending, enrollment ... of operating losses totaling more than $230 million, Minnesota,s ... of 1 percent of revenue (.39 percent or $65.9 million) ... Minnesota Council of Health Plans. Spending on medical care continues ...
Other Medicine News:Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 2Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 3Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 4Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 5Health News:MMR Information Systems, Inc. Announces Ticker Symbol Change 2Health News:MMR Information Systems, Inc. Announces Ticker Symbol Change 3Health News:Skilled Nursing Care Coalition Praises House Leadership for Budget Changes 2Health News:Best Practice Database Adds Research Highlighting Effective Data Gathering Approaches for Competitive Intelligence and Successful Activities for Gaining Maximum Payer Access and Insights 2Health News:Looking Forward: Health Information Technology and the American Recovery and Reinvestment Act 2Health News:Looking Forward: Health Information Technology and the American Recovery and Reinvestment Act 3Health News:Looking Forward: Health Information Technology and the American Recovery and Reinvestment Act 4Health News:Minnesota Health Plans Reserves, Investment Income Down 2Health News:Minnesota Health Plans Reserves, Investment Income Down 3
(Date:12/4/2009)... MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, ... U.S. Food and Drug Administration seeking approval to market ... a patent owned by Takeda Pharmaceutical Company Limited. ...
(Date:12/4/2009)... Dec. 4 Drs. Neal Shore and E. David ... the additional analysis of secondary end points of biochemical ... FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in ... Prostate cancer patients who received FIRMAGON 240/80 mg/month ...
(Date:12/4/2009)... AZN ) today announced that the US Food ... (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment ... SEROQUEL XR is the only medication in its class ... disorder as adjunctive therapy and acute depressive episodes associated ...
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 1U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 2U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 3U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 4U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 5U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 6BioSpecifics Technologies Corp to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5 2009 14669 1BioSpecifics Technologies Corp to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5 2009 14669 2Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 1Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 2Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 3Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 4Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 5Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 6Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 7
Part of the Octopus System which includes both the Starfish & Octopus3. The Starfish Heart Positioner simplifies cardiac positioning and minimizes the associated hemodynamic deterioration when compa...
... Introducing a simple way to lift the ... - the XPOSE 3. The XPOSE 3 ... during off-pump bypass surgery and to easily ... hemodynamics. Designed for both apical and non-apical ...
... Since its U.S. approval in 1992, ABIOMED's ... widely used advanced cardiac assist system in the ... only device approved by the U.S. Food and ... heart failure. ABIOMED continues to make advances ...
... Assist System (LVAS), manufactured by Arrow International, ... a destination therapy for patients with progressive, ... for which heart transplantation is not an ... intended as a bridge to transplant or ...
Medicine Products: